...
首页> 外文期刊>Biochemistry >Mitochondria Are Targets for the Antituberculosis Drug Rifampicin in Cultured Epithelial Cells
【24h】

Mitochondria Are Targets for the Antituberculosis Drug Rifampicin in Cultured Epithelial Cells

机译:线粒体是抗结核药物利福平在培养的上皮细胞中的靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Rifampicin is a widely used drag for antituberculosis therapy. Its target is the bacterial RNA polymerase. After entry into the human or mammalian organism, rifampicin is accumulated in cells of epithelial origin (kidneys, liver, lungs) where it induces apoptosis, necrosis, and fibrosis. The purpose of this study was to determine the intracellular mechanisms leading to rifampicin-induced pathological changes and cell death. We analyzed the survival and state of the chondriome of cultured epithelial cells of the SPEV line under the influence of rifampicin. Our data show that the drug induces pronounced pathological changes in the network and ultrastructure of mitochondria, and their dysfunction results in excessive production of reactive oxygen species and release of cytochrome c. These data suggest the initiation of the mitochondrial pathway of apoptosis. Simultaneously, we observed inhibition of cell proliferation and changes in morphology of the epithelial cells toward fibroblast-like appearance, which could indicate induction of epithelial-mesenchymal transition. Thus, mitochondria are the main potential target for rifampicin in cells of epithelial origin. We suggest that similar mechanisms of pathological changes can be induced in vivo in organs and tissues accumulating rifampicin during chemotherapy of bacterial infectious diseases.
机译:利福平是抗结核治疗中广泛使用的药物。它的靶标是细菌RNA聚合酶。进入人类或哺乳动物有机体后,利福平在上皮起源的细胞(肾脏,肝脏,肺脏)中积累,并在其中诱导凋亡,坏死和纤维化。这项研究的目的是确定导致利福平诱导的病理变化和细胞死亡的细胞内机制。我们分析了在利福平的影响下,SPEV系培养的上皮细胞软骨瘤的存活和状态。我们的数据表明,该药物在线粒体的网络和超微结构中诱导了明显的病理变化,其功能障碍导致活性氧的过度产生和细胞色素c的释放。这些数据表明凋亡的线粒体途径的启动。同时,我们观察到细胞增殖的抑制和上皮细胞向成纤维细胞样外观的形态变化,这可能表明诱导了上皮-间质转化。因此,线粒体是上皮来源细胞中利福平的主要潜在靶标。我们建议,在细菌感染性疾病的化疗期间,体内累积利福平的器官和组织可以诱导出类似的病理变化机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号